Pharmaceuticals

MDGL Stock Soars on FDA Liver Disease Approval

FDA approves first-ever NASH treatment, Rezdiffra, by Madrigal Pharmaceuticals Inc (NASDAQ: MDGL). Breakthrough for millions suffering from liver disease.

Eli Lilly's Zepbound Shows Short-Lived Weight Loss Benefits

Uncover key investment insights in the dynamic obesity drug market. Discover growth, value, and momentum strategies in this evolving healthcare sector.

AbbVie Stock in Focus with Strategic Cerevel Acquisition

AbbVie (ABBV) acquires Cerevel, enhancing its drug portfolio and opening new growth avenues in neuroscience for investors in ABBV stock.

BAYRY Stock: Bayer Faces Major Legal and Drug Dev Setbacks

Bayer's legal and pharmaceutical setbacks are something investors should pay attention to. These issues could impact BAYRY stock value and guide investment decisions.

Investors Watch as Novo Nordisk Pours Billions into Obesity Drugs

Novo Nordisk invests $2.3 billion in France to expand its weight-loss drug production, marking a significant move in the pharmaceutical industry.

FDA Approves Eli Lilly's Weight Loss Drug Zepbound

Eli Lilly's Tirzepatide drug, already approved for treating Type 2 diabetes as Mounjaro, has received FDA approval for weight management under the name Zepbound.

Gilead Sciences Marks Two Years of Robust Growth

Gilead Sciences reports robust Q3 growth, driven by oncology and HIV treatments, highlighting a solid pipeline and strategic expansion in global markets. The company is poised for a busy 2024 with multiple clinical updates.

Exact Sciences Records Stellar Q3 2023 Results

Exact Sciences showcases robust Q3 results, marking a turning point with increased revenue, diversified streams, and an upward trajectory.

EXACT Sciences Gears Up for Earnings Reveal

EXACT Sciences eyes a pivotal moment with its upcoming Q3 earnings report. The firm excels in ESG ratings and revenue, but operational costs raise questions.

Labor Dispute Hits CVS and Walgreens

A worker walkout at CVS and Walgreens poses investment questions. Learn more about potential impacts on retail investors.

IFF Eyes Billion-Dollar Pharma Unit Sale

IFF considers selling its pharma unit and Lucas Meyer cosmetics business. The sales could positively impact its debt profile and offer investment opportunities.

Are Biotech Penny Stocks Worth Investing In?

What can biotech penny stocks do for you? While investors might be attracted by the potential for outsize returns, there are serious risks to consider before throwing weight behind these cheap stocks.

Understanding Drug Development and Approval Process

New drugs and treatments have to undergo a long process of development, clinical trials and FDA approvals before they can start bringing in revenue for pharma and biotech companies.

An Introduction to Biopharma: A New Era in Medicine

Discover the cutting-edge world of biopharmaceuticals and how it's reshaping healthcare. From advanced therapies to life-changing drugs, explore the dynamic landscape of biopharma products.

Mapping the Future of Biopharma: Insights from McKinsey's Helix Report

Explore the McKinsey Helix Report and discover insights into the future success of the biopharmaceutical industry.